MrGuru Thursday, 09/19/19 07:29:01 AM Re: None Post # of 739 From last PR: "The FDA has given written guidance that prior study AP-003-A qualifies as a pivotal trial, and that successfully passing the current study, AP-013, would support the filing of our BLA." "In fact, the combined results of the prior single-injection trials indicate that the AP-013 KL 4 patients could report a difference of Ampion over saline that is 50% less than observed in the prior trials, and the clinical benefit of Ampion in both pain and function would still be statistically significant (p-value < 0.05)." This sounds good. I hope that the difference does not reduce but statistically things are looking good. Waiting anxiously for results. It they are good the price will go to da moon !!!